Skip to main content
SpringerLink
Log in

Natural History, Role of Biopsy, and Active Surveillance of Renal Masses

  • Chapter
  • First Online:
Renal Cancer

  • 981 Accesses

Abstract

With the increased utilization of abdominal imaging, we have witnessed a significant increase in incidentally detected clinically localized, small renal masses (SRMs) over the past few decades. While extirpation has remained the gold standard in managing SRMs, mortality rates from kidney cancer remain relatively unchanged. This suggests that a proportion of small renal masses may be indolent tumors that do not require surgical intervention. From these observations, active surveillance (AS) has emerged as an alternative management strategy in select patients with significant competing risks. The use of AS has provided the basis for describing the natural history of renal masses managed expectantly. Although the data are limited, we have observed that many incidental renal masses demonstrate slow growth kinetics with a low rate of progression to metastatic disease over an intermediate time period. While judicious use of AS in carefully selected patients appears to be a viable management strategy, prospective trials are necessary to define entry and intervention criteria for existing AS protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.

    Article  PubMed  Google Scholar 

  3. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31.

    Article  PubMed  CAS  Google Scholar 

  4. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331–4 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  5. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the national cancer data base. Cancer. 2008; 113(1):78–83.

    Article  PubMed  Google Scholar 

  6. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the national cancer data base, 1993 to 2004. J Urol. 2008;179(6):2131–5.

    Article  PubMed  Google Scholar 

  7. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5 [Comparative Study Review].

    Article  PubMed  CAS  Google Scholar 

  8. Corcoran AT, Russo P, Lowrance WT, Asnis-Alibozek A, Libertino JA, Pryma DA, Divgi CR, Uzzo RG. A review of contemporary data on surgically resected renal masses-benign or malignant? Urology. 2013;81(4):707–13.

    Google Scholar 

  9. Crispen PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, et al. Outcomes following partial nephrectomy by tumor size. J Urol. 2008;180(5):1912–7.

    Article  PubMed  Google Scholar 

  10. Remzi M, Ozsoy M, Klingler HC, Susani M, Waldert M, Seitz C, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006; 176(3):896–9.

    Article  PubMed  Google Scholar 

  11. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.

    Article  PubMed  Google Scholar 

  12. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13.

    Article  PubMed  Google Scholar 

  13. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271–9.

    Article  PubMed  Google Scholar 

  14. Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010;28(2):311–7 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  15. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58(6): 843–8.

    Article  PubMed  CAS  Google Scholar 

  16. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280(11):975–80 [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.].

    Article  PubMed  CAS  Google Scholar 

  17. Dall’Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112(8):1650–9.

    Article  PubMed  Google Scholar 

  18. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31.

    Google Scholar 

  19. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995;197(3): 589–97.

    PubMed  CAS  Google Scholar 

  20. Fujimoto N, Sugita A, Terasawa Y, Kato M. Observations on the growth rate of renal cell carcinoma. Int J Urol. 1995;2(2):71–6.

    Article  PubMed  CAS  Google Scholar 

  21. Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004;172(3): 863–6.

    Article  PubMed  Google Scholar 

  22. Oda T, Miyao N, Takahashi A, Yanase M, Masumori N, Itoh N, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001;8(9):473–7.

    Article  PubMed  CAS  Google Scholar 

  23. Abou Youssif T, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer. 2007; 110(5):1010–4.

    Article  PubMed  Google Scholar 

  24. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008;180(2):505–8. discussion 8–9.

    Article  PubMed  Google Scholar 

  25. Beisland C, Hjelle KM, Reisaeter LA, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol. 2009;55(6):1419–27.

    Article  PubMed  Google Scholar 

  26. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009;115(13):2844–52 [Research Support, N.I.H., Extramural].

    Article  PubMed  Google Scholar 

  27. Fernando HS, Duvuru S, Hawkyard SJ. Conservative management of renal masses in the elderly: our experience. Int Urol Nephrol. 2007;39(1):203–7.

    Article  PubMed  Google Scholar 

  28. Kouba E, Smith A, McRackan D, Wallen EM, Pruthi RS. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol. 2007;177(2):466–70. discussion 70.

    Article  PubMed  Google Scholar 

  29. Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy–natural history, complications, and outcome. Urology. 2004;64(5):909–13 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  30. Matsuzaki M, Kawano Y, Morikawa H, Shiga Y, Murata H, Komatsu H. Conservative management of small renal tumors. Hinyokika Kiyo. 2007;53(4): 207–11.

    PubMed  Google Scholar 

  31. Rosales JC, Haramis G, Moreno J, Badani K, Benson MC, McKiernan J, et al. Active surveillance for renal cortical neoplasms. J Urol. 2010;183(5):1698–702.

    Article  PubMed  Google Scholar 

  32. Siu W, Hafez KS, Johnston 3rd WK, Wolf Jr JS. Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar. Urol Oncol. 2007;25(2):115–9.

    Article  PubMed  Google Scholar 

  33. Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol. 2004;11(5):2407–10.

    PubMed  Google Scholar 

  34. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100(4):738–45 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  35. Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology. 2004;64(1): 49–52.

    Article  PubMed  Google Scholar 

  36. Wong JA, Rendon RA. Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol. Can Urol Assoc J. 2007;1(2):120–2.

    PubMed  Google Scholar 

  37. Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012;118(4):997–1006 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review].

    Article  PubMed  Google Scholar 

  38. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31 [Meta-Analysis Review].

    Article  PubMed  Google Scholar 

  39. Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):2033–6.

    Article  PubMed  Google Scholar 

  40. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 Pt 1):2217–20.

    Article  PubMed  Google Scholar 

  41. Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):2033–6 [Comparative Study Research Support, N.I.H., Extramural].

    Article  PubMed  Google Scholar 

  42. Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol. 2009;181(1):29–33. discussion -4.

    Article  PubMed  Google Scholar 

  43. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009;181(3):1020–7. discussion 7.

    Article  PubMed  Google Scholar 

  44. Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009;182(1):41–5.

    Article  PubMed  Google Scholar 

  45. Kunkle DA, Crispen PL, Li T, Uzzo RG. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol. 2007;177(5):1692–6. discussion 7.

    Article  PubMed  Google Scholar 

  46. Dodelzon K, Mussi TC, Babb JS, Taneja SS, Rosenkrantz AB. Prediction of growth rate of solid renal masses: utility of MR imaging features–preliminary experience. Radiology. 2012;262(3):884–93.

    Article  PubMed  Google Scholar 

  47. Duffey BG, Choyke PL, Glenn G, Grubb RL, Venzon D, Linehan WM, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172(1):63–5.

    Article  PubMed  Google Scholar 

  48. Uzzo RG. Renal masses–to treat or not to treat? If that is the question are contemporary biomarkers the answer? J Urol. 2008;180(2):433–4.

    Article  PubMed  Google Scholar 

  49. Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009;182(6):2585–9.

    Article  PubMed  Google Scholar 

  50. Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007; 178(2):429–34.

    Article  PubMed  Google Scholar 

  51. Crispen PL, Blute ML. Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies? Eur Urol. 2009;55(2):307–9.

    Article  PubMed  Google Scholar 

  52. Volpe A, Kachura JR, Geddie WR, Evans AJ, Gharajeh A, Saravanan A, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007;178(2):379–86.

    Article  PubMed  Google Scholar 

  53. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy–a renaissance? J Urol. 2008;179(1):20–7.

    Article  PubMed  Google Scholar 

  54. Wang R, Wolf Jr JS, Wood Jr DP, Higgins EJ, Hafez KS. Accuracy of percutaneous core biopsy in management of small renal masses. Urology. 2009;73(3):586–90. discussion 90-1.

    Article  PubMed  Google Scholar 

  55. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Coulange C. Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol. 2004;171(5):1802–5.

    Article  PubMed  Google Scholar 

  56. Maturen KE, Nghiem HV, Caoili EM, Higgins EG, Wolf Jr JS, Wood Jr DP. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007;188(2):563–70 [Randomized Controlled Trial].

    Article  PubMed  Google Scholar 

  57. Lechevallier E, Andre M, Barriol D, Daniel L, Eghazarian C, De Fromont M, et al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology. 2000;216(2):506–10.

    PubMed  CAS  Google Scholar 

  58. Leveridge MJ, Finelli A, Kachura JR, Evans A, Chung H, Shiff DA, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol. 2011;60(3):578–84.

    Article  PubMed  Google Scholar 

  59. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5. quiz 295.

    Article  PubMed  CAS  Google Scholar 

  60. Leveridge M, Shiff D, Chung H, Legere L, Fernandes K, Evans A, et al. Small renal mass needle core biopsy: outcomes of non-diagnostic percutaneous biopsy and role of repeat biopsy (abstract 821). J Urol. 2010;183(4):e321.

    Article  Google Scholar 

  61. Blumenfeld AJ, Guru K, Fuchs GJ, Kim HL. Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. Urology. 2010;76(3):610–3.

    Article  PubMed  Google Scholar 

  62. Khan AA, Shergill IS, Quereshi S, Arya M, Vandal MT, Gujral SS. Percutaneous needle biopsy for indeterminate renal masses: a national survey of UK consultant urologists. BMC Urol. 2007;7:10.

    Article  PubMed  Google Scholar 

  63. Wood BJ, Khan MA, McGovern F, Harisinghani M, Hahn PF, Mueller PR. Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. J Urol. 1999;161(5):1470–4.

    Article  PubMed  CAS  Google Scholar 

  64. Maturen KE, Nghiem HV, Caoili EM, Higgins EG, Wolf Jr JS, Wood Jr DP. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007;188(2):563–70.

    Article  PubMed  Google Scholar 

  65. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008;35(4):627–34. vii.

    Article  PubMed  Google Scholar 

  66. Rothman J, Crispen PL, Wong YN, Al-Saleem T, Fox E, Uzzo RG. Pathologic concordance of sporadic synchronous bilateral renal masses. Urology. 2008;72(1):138–42.

    Article  PubMed  Google Scholar 

  67. Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Rev Radiol. 1991;178(1): 253–8.

    CAS  Google Scholar 

  68. Abe M, Saitoh M. Selective renal tumour biopsy under ultrasonic guidance. Br J Urol. 1992;70(1): 7–11.

    Article  PubMed  CAS  Google Scholar 

  69. Auvert J, Abbou CC, Lavarenne V. Needle tract seeding following puncture of renal oncocytoma. Prog Clin Biol Res. 1982;100:597–8 [Case Reports].

    PubMed  CAS  Google Scholar 

  70. Gibbons RP, Bush Jr WH, Burnett LL. Needle tract seeding following aspiration of renal cell carcinoma. J Urol. 1977;118(5):865–7 [Case Reports].

    PubMed  CAS  Google Scholar 

  71. Kiser GC, Totonchy M, Barry JM. Needle tract seeding after percutaneous renal adenocarcinoma aspiration. J Urol. 1986;136(6):1292–3 [Case Reports].

    PubMed  CAS  Google Scholar 

  72. Shenoy PD, Lakhkar BN, Ghosh MK, Patil UD. Cutaneous seeding of renal carcinoma by Chiba needle aspiration biopsy. Case reports. Acta Radiol. 1991;32(1):50–2 [Case Reports].

    Article  PubMed  CAS  Google Scholar 

  73. Wehle MJ, Grabstald H. Contraindications to needle aspiration of a solid renal mass: tumor dissemination by renal needle aspiration. J Urol. 1986;136(2):446–8 [Case Reports].

    PubMed  CAS  Google Scholar 

  74. Giorgadze T, Qureshi F, Aulicino M, Jacques SM. Retroperitoneal recurrence of a stage 1 renal cell carcinoma four years following core biopsy and fine needle aspiration: possible needle tract seeding. Diagn Cytopathol. 2012 Jul 26. doi: 10.1002/dc.22901. [Epub ahead of print].

    Google Scholar 

  75. Jilani G, Mohamed D, Wadia H, Ramzi K, Meriem J, Houssem L, et al. Cutaneous metastasis of renal cell carcinoma through percutaneous fine needle aspiration biopsy: case report. Dermatol Online J. 2010;16(2):10 [Case Reports].

    PubMed  Google Scholar 

  76. Smith AD, Remer EM, Cox KL, Lieber ML, Allen BC, Shah SN, et al. Bosniak category IIF and III cystic renal lesions: outcomes and associations. Radiology. 2012;262(1):152–60.

    Article  PubMed  Google Scholar 

  77. Richter F, Kasabian NG, Irwin Jr RJ, Watson RA, Lang EK. Accuracy of diagnosis by guided biopsy of renal mass lesions classified indeterminate by imaging studies. Urology. 2000;55(3):348–52.

    Article  PubMed  CAS  Google Scholar 

  78. Truong LD, Todd TD, Dhurandhar B, Ramzy I. Fine-needle aspiration of renal masses in adults: analysis of results and diagnostic problems in 108 cases. Diagn Cytopathol. 1999;20(6):339–49.

    Article  PubMed  CAS  Google Scholar 

  79. Visapaa H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003;61(4):845–50.

    Article  PubMed  Google Scholar 

  80. Delahunt B, Bethwaite PB, Thornton A, Ribas JL. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome. Cancer. 1995;75(11):2714–9.

    Article  PubMed  CAS  Google Scholar 

  81. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma. Eur Urol. 1997;31(1):73–80.

    PubMed  CAS  Google Scholar 

  82. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005;173(3):725–8.

    Article  PubMed  CAS  Google Scholar 

  83. Zhang X, Takenaka I. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology. 2000;56(3):510–5.

    Article  PubMed  CAS  Google Scholar 

  84. Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999;35(1):133–7.

    Article  PubMed  CAS  Google Scholar 

  85. Bilim V, Yuuki K, Itoi T, Muto A, Kato T, Nagaoka A, et al. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer. 2008;98(5):941–9.

    Article  PubMed  CAS  Google Scholar 

  86. Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G. Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer. 1999;84(3):268–72.

    Article  PubMed  CAS  Google Scholar 

  87. Sabo E, Miselevich I, Bejar J, Segenreich M, Wald M, Moskovitz B, et al. The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma. Br J Urol. 1997;80(6):864–8.

    Article  PubMed  CAS  Google Scholar 

  88. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 2008;180(2):515–9.

    Article  PubMed  CAS  Google Scholar 

  89. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802–11.

    PubMed  CAS  Google Scholar 

  90. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;113(3):450–60.

    Article  PubMed  Google Scholar 

  91. Oda T, Takahashi A, Miyao N, Yanase M, Masumori N, Itoh N, et al. Cell proliferation, apoptosis, angiogenesis and growth rate of incidentally found renal cell carcinoma. Int J Urol. 2003;10(1):13–8.

    Article  PubMed  Google Scholar 

  92. Hicks RJ, Ware RE, Lau EW. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imag. 2006;6:S52–62.

    Article  Google Scholar 

  93. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Functional imaging of renal cell carcinoma. Nat Rev Urol. 2010;7(5):258–66.

    Article  PubMed  Google Scholar 

  94. Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using 18 F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96(4):540–6.

    Article  PubMed  Google Scholar 

  95. Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31(12): 788–9.

    Article  PubMed  Google Scholar 

  96. Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36(3):422–7.

    Article  PubMed  Google Scholar 

  97. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8(4):304–10.

    Article  PubMed  CAS  Google Scholar 

  98. Uzzo RG, Russo P, Chen D, Larson S, Bahnson R, Libertino JA, et al. The multicenter phase III redect trial: a comparative study of 124 I-girentuximab-PET/CT versus diagnostic CT for the pre-operative diagnosis of clear cell Renal Cell Carcinoma (ccRCC) (late breaking abstract; AUA, San Francisco). 2010.

    Google Scholar 

  99. Schachter LR, Bach AM, Snyder ME, Kattan MW, Russo P. The impact of tumour location on the histological subtype of renal cortical tumours. BJU Int. 2006;98(1):63–6.

    Article  PubMed  Google Scholar 

  100. Venkatesh R, Weld K, Ames CD, Figenshau SR, Sundaram CP, Andriole GL, et al. Laparoscopic ­partial nephrectomy for renal masses: effect of tumor location. Urology. 2006;67(6):1169–74. discussion 74.

    Article  PubMed  Google Scholar 

  101. Weizer AZ, Gilbert SM, Roberts WW, Hollenbeck BK, Wolf Jr JS. Tailoring technique of laparoscopic partial nephrectomy to tumor characteristics. J Urol. 2008;180(4):1273–8.

    Article  PubMed  Google Scholar 

  102. Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011;60(2):241–8 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  103. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000;163(3):730–6 [Research Support, U.S. Gov’t, P.H.S.].

    Article  PubMed  CAS  Google Scholar 

  104. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109(9):1763–8 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  105. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008;35(4):613–25.

    Article  PubMed  Google Scholar 

  106. Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009;182(6):2585–9 [Multicenter Study].

    Article  PubMed  Google Scholar 

  107. Kutikov A, Egleston BL, Smaldone MC, Canter D, Wong YN, Uzzo RG. Quantification of competing risks of death in patients with localized Renal Cell Carcinoma (RCC): a comprehensive nomogram incorporating co-morbidities. J Urol. 2012;188(6):2077–83.

    Google Scholar 

  108. Letourneau I, Ouimet D, Dumont M, Pichette V, Leblanc M. Renal replacement in end-stage renal disease patients over 75 years old. Am J Nephrol. 2003;23(2):71–7.

    Article  PubMed  CAS  Google Scholar 

  109. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

    Article  PubMed  CAS  Google Scholar 

  110. Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007;177(3):849–53. discussion 53-4.

    Article  PubMed  Google Scholar 

  111. Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008;26(5): 555–9.

    Article  PubMed  Google Scholar 

  112. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48(24 Pt 1):7067–71.

    PubMed  CAS  Google Scholar 

  113. Mues AC, Haramis G, Badani K, Gupta M, Benson MC, McKiernan JM, et al. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology. 2010;76(3):620–3.

    Article  PubMed  Google Scholar 

  114. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Nahon O, Coulange C. Follow-up of renal oncocytoma ­diagnosed by percutaneous tumor biopsy. Urology. 2005;66(6):1181–5.

    Article  PubMed  Google Scholar 

  115. Kawaguchi S, Fernandes KA, Finelli A, Robinette M, Fleshner N, Jewett MA. Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance. J Urol. 2011;186(4):1218–22.

    Article  PubMed  Google Scholar 

  116. Jewett MA, Finelli A, Morash C, Chin JL, Siemens R, Tanguay S, et al. Active surveillance of small renal masses: a prospective multi-center Canadian uro-oncology group trial: abstract no. 896. J Urol. 2009;181(4 (supplement)):320.

    Article  Google Scholar 

  117. Heilbrun ME, Yu J, Smith KJ, Dechet CB, Zagoria RJ, Roberts MS. The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: evidence from a Markov model. J Urol. 2012;187(1):39–43 [Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

  118. Chang SL, Cipriano LE, Harshman LC, Garber AM, Chung BI. Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. J Urol. 2011;185(5):1591–7 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Fox Chase Cancer Center of Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA, 19111, USA

    Anthony T. Corcoran M.D., Marc C. Smaldone M.D., Robert G. Uzzo M.D. & David Y. T. Chen M.D. FACS

Authors
  1. Anthony T. Corcoran M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc C. Smaldone M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert G. Uzzo M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Y. T. Chen M.D. FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Y. T. Chen M.D. FACS .

Editor information

Editors and Affiliations

  1. , Institute of Urology, Lahey Clinic, 41 Mall Road, Burlington, 01805, Massachusetts, USA

    John A Libertino

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Corcoran, A.T., Smaldone, M.C., Uzzo, R.G., Chen, D.Y.T. (2013). Natural History, Role of Biopsy, and Active Surveillance of Renal Masses. In: Libertino, J. (eds) Renal Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7236-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-7236-0_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-7235-3

  • Online ISBN: 978-1-4614-7236-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation